Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

X Xie, T Yu, X Li, N Zhang, LJ Foster, C Peng… - Signal transduction and …, 2023 - nature.com
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Human prostate cancer risk factors

DG Bostwick, HB Burke, D Djakiew… - … Journal of the …, 2004 - Wiley Online Library
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with
similar likelihood of neoplastic foci found within the prostates of men around the world …

MYC and prostate cancer

CM Koh, CJ Bieberich, CV Dang, WG Nelson… - Genes & …, 2010 - journals.sagepub.com
Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial
cancer affecting a majority of elderly men in Western nations. Its manifestation, however …

c-Myc in breast cancer.

DJ Liao, RB Dickson - Endocrine-related cancer, 2000 - erc.bioscientifica.com
Ever since Bishop and his co-workers discovered the c-myc gene in the late 1970s (Bishop
1982), voluminous literature has documented its central role in proliferation and malignant …

Efficacy of Antisense Morpholino Oligomer Targeted to c-myc in Prostate Cancer Xenograft Murine Model and a Phase I Safety Study in Humans

PL Iversen, V Arora, AJ Acker, DH Mason… - Clinical Cancer Research, 2003 - AACR
Purpose: The overexpression of c-myc associated with uncontrolled cell proliferation is a
frequent genetic event in androgen-refractory prostatic neoplasia. The purpose of this study …

Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo

Y Wang, S Liu, G Zhang, C Zhou, H Zhu, X Zhou… - Breast Cancer …, 2005 - Springer
Introduction Breast cancer is the leading cause of cancer death in women worldwide.
Elevated expression of c-Myc is a frequent genetic abnormality seen in this malignancy. For …

Targeting MYC in cancer therapy: RNA processing offers new opportunities

CM Koh, A Sabò, E Guccione - Bioessays, 2016 - Wiley Online Library
MYC is a transcription factor, which not only directly modulates multiple aspects of
transcription and co‐transcriptional processing (eg RNA‐Polymerase II initiation, elongation …

Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 …

Z Peng, Y Wang, J Fan, X Lin, C Liu, Y Xu, W Ji… - Scientific Reports, 2017 - nature.com
Our previous studies demonstrated that volatile oil from saussurea lappa root (VOSL), rich in
two natural sesquiterpene lactones, costunolide (Cos) and dehydrocostuslactone (Dehy) …

1α,25-Dihydroxyvitamin D3 Reduces c-Myc Expression, Inhibiting Proliferation and Causing G1 Accumulation in C4-2 Prostate Cancer Cells

JANP Rohan, NL Weigel - Endocrinology, 2009 - academic.oup.com
There is an inverse correlation between exposure to sunlight (the major source of vitamin D)
and the risk for prostate cancer, the most common noncutaneous cancer and second most …

htert expression correlates with MYC over‐expression in human prostate cancer

A Latil, D Vidaud, A Valéri, G Fournier… - … journal of cancer, 2000 - Wiley Online Library
Expression of the telomerase catalytic sub‐unit (htert) constitutes a key step in the
development of human cancer. Although htert regulation is still unclear, several studies …